# EIKN (Eikon Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Eikon Therapeutics, Inc. reported $706.2M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/EIKN
- Markdown: https://convexityos.com/fundamentals/EIKN.md
- SEC CIK: 0001861123
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:39 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001861123&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $461.7M | Total debt: $249.5M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $71.83M | $75.46M | $70.05M | $59.31M | $69.19M | $56.59M |
| Total Operating Expenses | $90.55M | $93.39M | $87.34M | $74.75M | $109.6M | $71.38M |
| **Operating Income** | -$90.55M | -$93.39M | -$87.34M | -$74.75M | -$109.6M | -$71.38M |
| **EBITDA** | -$85.55M | -$88.29M | -$82.12M | -$69.25M | -$105.4M | -$67.59M |
| **Net Income** | -$86.11M | -$88.41M | -$82.96M | -$71.14M | -$105.2M | -$68.24M |
| Basic EPS | -$1.59 | -$1.63 | -$2.46 | -$24.24 | -$36.94 | -$26.91 |
| **Diluted EPS** | -$1.59 | -$1.63 | -$2.46 | -$24.24 | -$36.94 | -$26.91 |
| Basic Shares Outstanding | 54.2M | 54.1M | 33.7M | 2.9M | 2.8M | 2.8M |
| Diluted Shares Outstanding | 54.2M | 54.1M | 33.7M | 2.9M | 2.8M | 2.8M |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $98.48M | $142.6M | $161.2M | $104.9M |
| Short-Term Investments | $363.2M | $388.6M | $351.0M | $231.1M |
| **Cash & Short-Term Investments** | $461.7M | $531.2M | $512.2M | $336.0M |
| **Total Current Assets** | $478.1M | $547.0M | $529.5M | $348.9M |
| Property, Plant & Equipment, Net | $128.6M | $133.1M | $138.1M | $142.9M |
| Long-Term Investments | -- | -- | $83.83M | -- |
| Other Non-Current Assets | $463K | $539K | $556K | $4.18M |
| **Total Non-Current Assets** | $228.1M | $232.6M | $321.3M | $245.8M |
| **Total Assets** | $706.2M | $779.6M | $850.8M | $594.7M |
| Accounts Payable | $6.12M | $6.56M | $6.00M | $681K |
| **Total Current Liabilities** | $66.27M | $55.30M | $45.06M | $55.01M |
| Other Non-Current Liabilities | $15.00M | $15.00M | $10.00M | $10.00M |
| **Total Non-Current Liabilities** | $255.6M | $257.8M | $255.1M | $257.3M |
| **Total Liabilities** | $321.9M | $313.1M | $300.2M | $312.3M |
| **Total Debt (incl. Leases)** | $249.5M | $252.2M | $254.8M | $257.3M |
| Common Stock | $5.0K | $5.0K | $5.0K | $0 |
| Retained Earnings | -$1.18B | -$1.09B | -$1.00B | -$920.5M |
| **Total Stockholders' Equity** | $384.3M | $466.5M | $550.7M | -$879.0M |
| Total Equity | $384.3M | $466.5M | $550.7M | -$879.0M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$86.11M | -$88.41M | -$82.96M | -$71.14M | -$105.2M | -$68.24M |
| Depreciation & Amortization | $5.00M | $5.10M | $5.21M | $5.50M | $4.20M | $3.79M |
| Stock-Based Compensation | $3.75M | $4.22M | $2.78M | $3.99M | $7.21M | $2.97M |
| Change in Payables | -$383K | $497K | $5.32M | $363K | -$2.91M | $2.28M |
| **Operating Cash Flow** | -$69.19M | -$64.96M | -$89.80M | -$59.53M | -$32.74M | -$54.52M |
| Capital Expenditure | -$419K | -$251K | -$262K | -$2.60M | -$21.72M | -$22.36M |
| **Free Cash Flow** | -$69.61M | -$65.21M | -$90.06M | -$62.14M | -$54.45M | -$76.88M |
| Purchases of Investments | -$49.64M | -$79.82M | -$307.0M | -$68.72M | -$68.91M | -$252.5M |
| **Investing Cash Flow** | $24.94M | $46.43M | -$203.2M | $27.68M | -$35.88M | -$213.9M |
| Common Stock Issued | $157K | $25K | $277K | $261K | $529K | $21K |
| **Financing Cash Flow** | $157K | $25K | $349.3M | $211K | $519K | $350.2M |
| **Net Change in Cash** | -$44.09M | -$18.50M | $56.29M | -$31.65M | -$68.09M | $81.86M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 7.21x | 9.89x | 11.75x | -- | -- | -- |
| Quick Ratio | 6.97x | 9.61x | 11.37x | -- | -- | -- |
| Debt to Equity | 0.65x | 0.54x | 0.46x | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
